UBS Group Increases Agilent Technologies (NYSE:A) Price Target to $180.00

Agilent Technologies (NYSE:A) had its target price increased by analysts at UBS Group from $170.00 to $180.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the medical research company’s stock. UBS Group’s price target indicates a potential upside of 13.85% from the company’s previous close.

Other equities analysts have also recently issued reports about the company. JPMorgan Chase & Co. lifted their price target on Agilent Technologies from $165.00 to $180.00 and gave the stock an “overweight” rating in a research note on Tuesday. Weiss Ratings reissued a “hold (c)” rating on shares of Agilent Technologies in a report on Wednesday, October 8th. Bank of America boosted their price objective on shares of Agilent Technologies from $150.00 to $165.00 and gave the company a “neutral” rating in a research report on Tuesday. Barclays increased their target price on shares of Agilent Technologies from $145.00 to $165.00 and gave the stock an “equal weight” rating in a report on Tuesday. Finally, Wall Street Zen upgraded Agilent Technologies from a “hold” rating to a “buy” rating in a report on Friday, October 3rd. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $157.54.

Agilent Technologies Price Performance

Shares of A traded up $4.51 during trading hours on Tuesday, reaching $158.11. 2,090,658 shares of the company’s stock traded hands, compared to its average volume of 1,903,211. Agilent Technologies has a 12 month low of $96.43 and a 12 month high of $160.27. The company has a current ratio of 2.25, a quick ratio of 1.71 and a debt-to-equity ratio of 0.53. The stock has a market cap of $44.82 billion, a PE ratio of 37.10, a price-to-earnings-growth ratio of 4.67 and a beta of 1.29. The firm’s 50 day simple moving average is $140.20 and its 200-day simple moving average is $125.68.

Agilent Technologies (NYSE:A) last announced its earnings results on Monday, November 24th. The medical research company reported $1.59 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.01. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The business had revenue of $1.86 billion for the quarter, compared to the consensus estimate of $1.83 billion. During the same period last year, the firm posted $1.46 earnings per share. Agilent Technologies’s quarterly revenue was up 9.4% on a year-over-year basis. Agilent Technologies has set its Q1 2026 guidance at 1.350-1.380 EPS. FY 2026 guidance at 5.860-6.000 EPS. Equities analysts expect that Agilent Technologies will post 5.58 EPS for the current year.

Insider Buying and Selling at Agilent Technologies

In related news, CEO Padraig Mcdonnell sold 911 shares of the stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $143.24, for a total value of $130,491.64. Following the completion of the transaction, the chief executive officer directly owned 32,058 shares in the company, valued at $4,591,987.92. This trade represents a 2.76% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.26% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Agilent Technologies

Several institutional investors and hedge funds have recently made changes to their positions in A. Resona Asset Management Co. Ltd. raised its position in shares of Agilent Technologies by 6.2% during the second quarter. Resona Asset Management Co. Ltd. now owns 98,400 shares of the medical research company’s stock valued at $11,631,000 after buying an additional 5,767 shares during the last quarter. TrueMark Investments LLC bought a new position in shares of Agilent Technologies during the 2nd quarter valued at approximately $1,999,000. Fenimore Asset Management Inc raised its stake in Agilent Technologies by 2.7% during the second quarter. Fenimore Asset Management Inc now owns 180,880 shares of the medical research company’s stock valued at $21,346,000 after purchasing an additional 4,823 shares in the last quarter. Nuance Investments LLC raised its position in shares of Agilent Technologies by 13.5% during the 2nd quarter. Nuance Investments LLC now owns 80,698 shares of the medical research company’s stock valued at $9,523,000 after buying an additional 9,628 shares in the last quarter. Finally, Asset Management One Co. Ltd. raised its position in Agilent Technologies by 3.4% during the second quarter. Asset Management One Co. Ltd. now owns 124,577 shares of the medical research company’s stock valued at $14,701,000 after purchasing an additional 4,152 shares during the period. Institutional investors own 87.41% of the company’s stock.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.